{"id":562053,"date":"2022-09-01T00:00:00","date_gmt":"2022-09-01T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidon0107-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-epidemiology-asia-pacific\/"},"modified":"2026-03-31T10:38:37","modified_gmt":"2026-03-31T10:38:37","slug":"epidon0107-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-epidemiology-asia-pacific","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidon0107-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-epidemiology-asia-pacific\/","title":{"rendered":"Non-Hodgkin&#8217;s Lymphoma and Chronic Lymphocytic Leukemia &#8211; Epidemiology &#8211; Asia-Pacific"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of non-Hodgkin\u2019s lymphoma (<abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr>) and chronic lymphocytic leukemia (<abbr title=\"chronic lymphocytic leukemia\">CLL<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr> and <abbr title=\"chronic lymphocytic leukemia\">CLL<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr> and <abbr title=\"chronic lymphocytic leukemia\">CLL<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people diagnosed with <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr> and <abbr title=\"chronic lymphocytic leukemia\">CLL<\/abbr>, how many in each of the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr> and <abbr title=\"chronic lymphocytic leukemia\">CLL<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <span class=\"abbreviation-guard\">MS<\/span> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the countries considered in this report. These patient flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 86 <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr> and <abbr title=\"chronic lymphocytic leukemia\">CLL<\/abbr> patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed first-line drug-treatable population of <abbr title=\"chronic lymphocytic leukemia\">CLL<\/abbr> + small lymphocytic lymphoma (<abbr title=\"small lymphocytic lymphoma\">SLL<\/abbr>).<\/li>\n<li>Diagnosed prevalent cases of diffuse large B-cell lymphoma (<abbr title=\"diffuse large B-cell lymphoma\">DLBCL<\/abbr>) transformed from follicular lymphoma (<abbr title=\"follicular lymphoma\">FL<\/abbr>).<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr>.<\/li>\n<li>Diagnosed third-line drug-treatable <abbr title=\"diffuse large B-cell lymphoma\">DLBCL<\/abbr> population.<\/li>\n<li>Transformed incident cases of <abbr title=\"follicular lymphoma\">FL<\/abbr> to <abbr title=\"diffuse large B-cell lymphoma\">DLBCL<\/abbr>.<\/li>\n<li>Diagnosed incident cases of <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr>.<\/li>\n<li>Diagnosed first-line drug-treatable mantle cell lymphoma (<abbr title=\"mantle cell lymphoma\">MCL<\/abbr>) population.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"follicular lymphoma\">FL<\/abbr>.<\/li>\n<li>Diagnosed incident cases of <abbr title=\"mantle cell lymphoma\">MCL<\/abbr>.<\/li>\n<li>\u2026 and many more (details available on request).<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-562053","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hematological-malignancies","biopharma-therapy-areas-hematology","biopharma-therapy-areas-hodgkins-lymphoma","biopharma-therapy-areas-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia","biopharma-product-epidemiology","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/562053","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/562053\/revisions"}],"predecessor-version":[{"id":562451,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/562053\/revisions\/562451"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=562053"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}